The oxidative functionalization of olefins is a common method for the formation of vicinal carbon-heteroatom bonds. However, oxidative methods to transform allenes into synthetic motifs containing three contiguous carbon-heteroatom bonds are much less developed. The use of bicyclic methylene aziridines (MAs), prepared via intramolecular allene aziridination, as scaffolds for functionalization of all three allene carbons, among other reactions, is described herein.

The oxidative functionalization of olefins is a common method for the formation of vicinal carbon-heteroatom bonds. However, oxidative methods to transform allenes into synthetic motifs containing three contiguous carbon-heteroatom bonds are much less developed. The use of bicyclic methylene aziridines (MAs), prepared via intramolecular allene aziridination, as scaffolds for functionalization of all three allene carbons, among other reactions, is described herein.

The present disclosure relates to a compound of Chemical Formula I, a solvate, a stereoisomer or a pharmaceutically acceptable salt thereof. Further, the present disclosure relates to a pharmaceutical composition for preventing or treating various ophthalmic such diseases as diabetic retinopathy, glaucoma, uveitis, wet and dry macular degeneration, and age-related macular degeneration, including the compound of Chemical Formula I, the solvate, the stereoisomer, or the pharmaceutically acceptable salt thereof as an active ingredient. A novel low molecular compound of the present disclosure exhibits an excellent effect in preventing and improving various ophthalmic diseases caused by retinal degeneration by inhibiting BET proteins to improve inflammation caused by retinal damage caused by epigenetic changes.

The present disclosure relates to a compound of Chemical Formula I, a solvate, a stereoisomer or a pharmaceutically acceptable salt thereof. Further, the present disclosure relates to a pharmaceutical composition for preventing or treating various ophthalmic such diseases as diabetic retinopathy, glaucoma, uveitis, wet and dry macular degeneration, and age-related macular degeneration, including the compound of Chemical Formula I, the solvate, the stereoisomer, or the pharmaceutically acceptable salt thereof as an active ingredient. A novel low molecular compound of the present disclosure exhibits an excellent effect in preventing and improving various ophthalmic diseases caused by retinal degeneration by inhibiting BET proteins to improve inflammation caused by retinal damage caused by epigenetic changes.